



SOCIOECONOMIC DISPARITIES IN ACCESS TO TREATMENT AND THEIR IMPACT ON COLORECTAL CANCER SURVIVAL

Catherine Lejeune, Franco Sassi, Libby Ellis, Sara Godward, Vivian Mak,
Matthew Day, B Rachet

► To cite this version:

Catherine Lejeune, Franco Sassi, Libby Ellis, Sara Godward, Vivian Mak, et al.. SOCIOECONOMIC DISPARITIES IN ACCESS TO TREATMENT AND THEIR IMPACT ON COLORECTAL CANCER SURVIVAL. *International Journal of Epidemiology*, 2010, 39 (3), pp.710. 10.1093/ije/DYQ048 . hal-00584272

HAL Id: hal-00584272

<https://hal.science/hal-00584272>

Submitted on 8 Apr 2011

HAL is a multi-disciplinary open access archive for the deposit and dissemination of scientific research documents, whether they are published or not. The documents may come from teaching and research institutions in France or abroad, or from public or private research centers.

L'archive ouverte pluridisciplinaire **HAL**, est destinée au dépôt et à la diffusion de documents scientifiques de niveau recherche, publiés ou non, émanant des établissements d'enseignement et de recherche français ou étrangers, des laboratoires publics ou privés.

SOCIOECONOMIC DISPARITIES IN ACCESS TO TREATMENT AND THEIR IMPACT ON COLORECTAL CANCER SURVIVAL

Journal:	<i>International Journal of Epidemiology</i>
Manuscript ID:	IJE-2009-07-0647.R1
Manuscript Type:	Original Article
Date Submitted by the Author:	23-Dec-2009
Complete List of Authors:	<p>Lejeune, Catherine; INSERM U866, Univ Bourgogne, Faculty of Medicine</p> <p>Sassi, Franco; The London School of Economics and Political Science (LSE), Department of Social Policy; Organisation for Economic Cooperation and Development (OECD), Health Division</p> <p>Ellis, Libby; London School of Hygiene & Tropical Medicine (LSHTM), Cancer and Public Health Unit, Department of Epidemiology & Population Health</p> <p>Godward, Sara; Eastern Cancer Registration and Information Centre</p> <p>Mak, Vivian; King's College London, Thames Cancer Registry</p> <p>Day, Matthew; Northern and Yorkshire Cancer Registry & Information Service</p> <p>Rachet, B; London School of Hygiene & Tropical Medicine, Cancer and Public Health Unit, Department of Epidemiology & Population Health</p>
Key Words:	colorectal neoplasms, mortality, social class

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

SOCIOECONOMIC DISPARITIES IN ACCESS TO TREATMENT AND THEIR IMPACT
ON COLORECTAL CANCER SURVIVAL

Lejeune C¹, Sassi F², Ellis L³, Godward S⁴, Mak V⁵, Day M⁶, Rachet B³

¹ Inserm, U866, 7 bd Jeanne d’Arc, BP 87900, F-21079 DIJON Cedex, France ; Univ
Bourgogne, 7 bd Jeanne d’Arc, BP 87900, F-21079 DIJON Cedex, France

² Department of Social Policy, The London School of Economics and Political Science (LSE);
and Health Division, Organisation for Economic Cooperation and Development (OECD)

³ London School of Hygiene & Tropical Medicine (LSHTM), Cancer and Public Health Unit,
Department of Epidemiology & Population Health

⁴ Eastern Cancer Registration and Information Centre

⁵ King’s College London, Thames Cancer Registry

⁶ Northern and Yorkshire Cancer Registry & Information Service

Correspondence to: C. Lejeune, Inserm, U866, 7 bd Jeanne d’Arc, BP 87900, F-21079 DIJON
Cedex, France ; Univ Bourgogne, 7 bd Jeanne d’Arc, BP 87900, F-21079 DIJON Cedex,
France . Tel: (+ 33) 3 80 39 34 88, FAX: (+ 33) 3 80 66 82 51. E-mail: catherine.lejeune@u-
bourgogne.fr.

Word count: 3092

Running title: Socioeconomic disparities in colorectal cancer survival

Medical Subject headings: colorectal neoplasms; mortality; social class

Acknowledgements: We would like to thank Michel Coleman and Jean Faivre for their support and comments, David Forman, Henrik Møller, and Jem Rashbass for providing access to the cancer registry data used in the study.

Confidentiality clause: This study was approved by the Eastern MREC and by PIAG in 2004.

Statement:

- I confirm that Michel Coleman and Jean Faivre, David Forman, Henrik Møller, and Jem Rashbass have confirmed their agreement.
- I confirm that this material has not been published previously in a substantively similar form.
- I confirm that the manuscript has been carefully edited by someone with an excellent mastery of the English language.
- All authors will personally vouch for the validity of the article
- References have been checked for accuracy and completeness and prepared in the in the Vancouver Style

Key messages box:

- In England, access to treatment for colorectal cancer and three-year relative survival vary according to a socioeconomic gradient.
- More deprived patients are more likely to receive late treatment (4th to 6th month) or no treatment within 6 months since their first contact with the National Health Service, compared with less deprived patients.
- The socioeconomic gradient in relative survival is greatly reduced among patients receiving early treatment (within the first month), even after accounting for differences in age at diagnosis and tumour stage.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

ABSTRACT

Background: Significant socioeconomic disparities have been reported in survival from colorectal cancer in a number of countries, which remain largely unexplained. We assessed whether possible differences in access to treatment among socioeconomic groups may contribute to those disparities, using a population-based approach.

Methods: We retrospectively studied 71,917 records of colorectal cancer patients, diagnosed between 1997 and 2000, linked to area-level socioeconomic information (Townsend index), from three cancer registries in England. Access to treatment was measured as a function of delay in receipt of treatment. We assessed socioeconomic differences in access through logistic regression models. Based on relative survival up to three years after diagnosis, we estimated excess hazard ratios of death (EHR) for different socioeconomic groups.

Results: Compared to more affluent patients, deprived patients had poorer survival (EHR=1.20; 95%CI [1.16-1.25]), were less likely to receive any treatment within six months (OR=0.87, 95%CI 0.82-0.92) and if treated, were more likely to receive late treatment. No disparities in survival were detected among patients receiving treatment within one month from diagnosis. Disparities existed among patients receiving later or no treatment (EHR=1.30; 95%CI [1.22-1.39]), and persisted after adjustment for age and stage at diagnosis (EHR=1.15; 95%CI [1.08-1.24]).

Conclusions: Tumour stage helped explain socioeconomic disparities in colorectal cancer survival. Disparities were also greatly attenuated among patients receiving early treatment. Aspects other than those captured by our measure of access, such as quality of care and patient preferences in relation to treatment, might contribute to a fuller explanation.

INTRODUCTION

Colorectal cancer is one of the most common causes of cancer-related death in most industrialised countries with 640,000 deaths worldwide per year¹. In many parts of the world, there is now strong evidence that colorectal cancer survival differs between socioeconomic groups²⁻⁴. Disparities are found even in countries with universal entitlement to health care, like the United Kingdom, where the health system is inspired by an egalitarian ethos, which prompts challenging questions on the origins of such disparities. It has been suggested that disparities in survival may be driven by differences in stage at diagnosis⁵, although a number of studies using ecological measures of socioeconomic condition failed to establish such link⁶⁻⁸. Differences in treatment are also among the factors that may contribute to explaining disparities in survival from colorectal cancer^{2,4}, but limited evidence has been produced so far in this direction. Socioeconomic disparities in type of, and access to, treatment have been examined in a number of studies^{7,9-11}. These studies, however, did not assess the impact of disparities in treatment on survival and used heterogeneous measures of socioeconomic status and access to treatment, which makes comparisons across studies very difficult.

Given this background, we designed a new population-based study to explore the associations between deprivation, access to treatment and survival for colorectal cancer in the areas covered by 3 regional cancer registries in England. The final aim of the study was to assess whether differences in access to treatment contribute to explaining socioeconomic disparities in survival from colorectal cancer.

DATA AND METHODS

Patient-level data

We obtained patient-level cancer registration data from the Thames Cancer Registry, the Eastern Cancer Registration and Information Centre and the Northern and Yorkshire Cancer

Registry & Information Service in England, covering populations of about 13.5, 2.7, and 6.6 million, respectively. Patients diagnosed with a first primary invasive colorectal cancer between January 1997 and 2000 and registered by one of the three cancer registries were deemed eligible for inclusion. Pathways of care and vital status for these patients were observed through to 31st December 2003. We identified 76,078 eligible patients, 3751 (4.9%) of these were excluded because tumour registration was based on a death certificate only. A further 410 patients were excluded because they could not be assigned to a socioeconomic group. The statistical analyses were conducted on the remaining 71,917 patients (38,085 for the Thames Cancer Registry, 9785 for the Eastern Cancer Registration and Information Centre, and 24,047 for the Northern and Yorkshire Cancer Registry & Information Service). Tumours were characterized according to their anatomic site¹², their morphology and behaviour (ICD-O-2), and their stage. The morphology grouping was based on the classification proposed by Gatta *et al.*¹³. Tumour stage was classified on the basis of AJCC stage groupings (I, local extension; II, extension beyond organ; III, regional lymph node involvement; and IV, metastatic disease)¹⁴. Two measures reflecting access to treatment were used in the analyses. The first is receipt of any treatment within 6 months from the first known contact with the National Health Service (NHS). The second, for patients who did receive a treatment within 6 months, is time-to-treatment, i.e. the time elapsed between the first known contact and the time of the first treatment received (surgery for 95% of the patients in the study). In many cases, the date of first contact corresponded to the date of diagnosis recorded in cancer registries, and normally corresponds to a specialist consultation or a diagnostic investigation. No primary care consultations are recorded in the three participating registries.

Area-level socioeconomic data

Cancer registries in England do not routinely collect information on individual socioeconomic status. Therefore, research on socioeconomic disparities in cancer normally relies on ecological measures of deprivation. We selected a measure of area deprivation widely used in health and health care research in England, the Townsend index¹⁵, calculated at the ward level using data from the 2001 census¹⁶. The average population of a ward in England is approximately 5500 individuals. Townsend scores were assigned to patients on the basis of postcodes of residence at the time of diagnosis (full postcodes include on average of 15-20 households). Patients were then assigned to quintiles of the national distribution of wards by level of deprivation. Therefore, a patient in the highest socioeconomic group, for instance, is one living in an area which is part of the most affluent fifth of wards in the country. The five categories were labelled from the least deprived (1 = affluent) to the most deprived (5 = poor).

Statistical analysis

The association between socioeconomic condition and receipt of treatment within 6 months was investigated with a logistic model, while a multinomial logistic model was used to assess the relationships between deprivation and time-to-treatment. The latter was categorized as follows: no treatment received within 6 months from the first known contact with the NHS; treatment received within one week; treatment in the 2nd to 4th week; treatment in the 2nd to 3rd month; and treatment in the 4th to 6th month. The following covariates were introduced into both models: age (five age groups); tumour stage at diagnosis; and type of treatment (surgery, chemotherapy, radiotherapy).

Relative survival was estimated up to three years after diagnosis using a maximum likelihood approach for individual-level data records¹⁷. Relative survival is the standard approach to estimating population-based survival. It is calculated as the ratio of the observed probability

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

of survival to the probability that would have been expected for an individual with the same characteristics (age, gender, socioeconomic condition) in the general population. Background mortality was derived from population life tables. Because of wide variations in background mortality between deprivation groups, complete life tables were built by deprivation category for 1998 using mid-year population estimates and the mean annual number of deaths during a period of three years centred on the index year¹⁸. We used life tables defined by quintiles of the income domain score of the Index of Multiple Deprivation (IMD 2000)¹⁹ because life tables by Townsend Index were not available. A generalised lineal model with Poisson error²⁰ was used to estimate the excess hazard ratio of death (EHR) associated with deprivation, and the confounding effects of age, receipt of treatment and time-to-treatment, and stage at diagnosis. Interactions between deprivation and access variables and between deprivation and follow-up time were also investigated.

Tumour stage at diagnosis was missing for 12,139 (17%) patients. A ten-fold multiple imputation approach was applied to the data to account for this incompleteness²¹⁻²⁴. The associations between missing values and recorded values enable the imputation model to fill in the missing values, using records in which stage information is available. The imputation model, in this case an ordered logistic regression, was iteratively applied to generate ten ‘completed’ datasets, generally deemed sufficient to obtain reliable estimates. The parameters of interest and their variance were estimated in each dataset and then pooled using multiple imputation rules.

RESULTS

Cancer patients in the five socioeconomic groups had similar distributions by age and gender. No differences among socioeconomic groups were found in relation to tumour characteristics,

with the exception of stage at diagnosis, with overall slightly more advanced disease in more deprived groups (17% of local tumour and 29% of metastatic tumour in the bottom group vs. 24% and 25%, respectively, in the most affluent group). Patients in lower socioeconomic groups were slightly less likely to have received treatment within 6 months after the first known contact with the NHS. Generally, more affluent patients had received treatment earlier than most deprived patients (Table 1). The proportion of missing tumour stage tended to increase, though very little, with deprivation (Table 1). When limited on the 59,848 complete cases, the proportion of advanced stages increased a little and this increase was slightly more markedly with deprivation. The patterns observed on the completed data sets (Table 1) between deprivation and treatment, were also slightly accentuated among the complete cases.

Table 1 here

These descriptive findings were confirmed by univariable regression analyses of the effects of socioeconomic status on access to treatment, showing that the odds of late treatment, or no treatment within 6 months, increase as deprivation increases (upper section of Table 2). Adjusting for age at diagnosis and tumour stage did not meaningfully alter the association between deprivation and treatment (lower section of Table 2). In summary, socioeconomic status was associated with access to treatment. More deprived patients were more likely to receive late treatment (4th to 6th month) or no treatment within 6 months, and less likely to receive treatment within one month from their first contact with the NHS.

Table 2 here

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

We investigated the impact of differences in access to treatment on disparities in survival among socioeconomic groups up to three years after diagnosis. We calculated excess hazard ratios of death, reflecting relative risks of cancer-related mortality, for most deprived socioeconomic groups relative to the most affluent group. EHRs increased with increasing deprivation, up to a value of 1.20; 95%CI [1.16-1.25], for the most deprived socioeconomic group (Table 3). Of the patient and tumour characteristics accounted for in the analysis, only tumour stage had a confounding effect on socioeconomic disparities in survival, with a small reduction of EHRs for the lower socioeconomic groups (from 1.20; 95%CI [1.16-1.25], to 1.13; 95%CI [1.09-1.16] for the most deprived group, results not shown). Accounting for receipt of treatment within 6 months had hardly any effect on overall EHRs (for all patients). However, patterns of excess mortality hazard varied among patients treated with different degrees of delay. The socioeconomic gradient in mortality was substantially reduced, or even disappeared, among patients who had received early treatment (within the first month). Conversely, the gradient was steeper among patients who had not been treated within 6 months. Adjusting for age at diagnosis and tumour stage once again attenuated, but did not eliminate, excess mortality for the lower socioeconomic groups. We did not find any strong evidence for an interaction between deprivation and time since diagnosis over the three-year follow-up.

Table 3 here

DISCUSSION

Using a population-based approach, we found an important socioeconomic gradient in three-year survival from colorectal cancer, with lowest mortality among the most affluent patients. This gradient was only partially explained by differences in stage at diagnosis among socioeconomic groups. We also showed important socioeconomic differences in access to

treatment, with more deprived patients more likely to receive late treatment or no treatment within six months from their first contact with the NHS, even after accounting for differences in stage at diagnosis. Socioeconomic disparities in survival were greatly attenuated among patients receiving early treatment, and persisted otherwise.

The existence of a socioeconomic gradient in survival from colorectal cancer in the UK had been shown in previous studies^{3,25,26}. The role played by tumour stage in explaining socioeconomic disparities in survival remains controversial^{6-8,27}, although our findings are consistent with evidence reported in several recent studies confirming that differences in stage at diagnosis are responsible for at least part of the observed socioeconomic gradient in survival²⁸⁻³⁰. Socioeconomic disparities in access to care in England have been documented with reference to a range of health services³¹, and specifically with reference to treatment for colorectal cancer. Tumour stage, however, does not appear to play a key role in the choice of surgical procedure in colorectal cancer¹⁰. Our study is probably the first population-based assessment of the impact of differences in access to treatment on socioeconomic disparities in cancer survival. No socioeconomic disparities in survival were found among colorectal cancer patients enrolled in clinical trials, who therefore received the same treatments³². The absence of a socioeconomic gradient in survival in patients receiving early treatment in our study is in line with the latter evidence.

Information on tumour stage was not available for almost one fifth of the patients. These patients tended to be slightly more deprived, older, and had lower relative survival. This suggests that the missingness mechanism was not completely random, and analyses limited to complete cases would likely be biased. Multiple imputation approaches aim at providing unbiased estimates on the assumption of a random distribution of missing observations.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Therefore, the imputation model incorporated all the relevant available information such as socio-demographic and tumour variables as well as time since diagnosis and vital status³³. Compared to the observed cases, the imputed values were more likely to be of advanced stage: on average, 15% local stage and 36% metastatic stage, compared to 21% and 25%, respectively, among the complete cases. All analyses were repeated on the 59,848 complete cases and results compared to those derived from the 10 imputed datasets³⁴. The associations between deprivation and the receipt of treatment or time to treatment were less strong, but followed similar patterns. The conclusions based on the excess hazard models estimated from the complete cases would be the same as those based on the results shown in Table 3.

There were a number of limitations in our data concerning treatments received by colorectal cancer patients. It was not possible to distinguish between elective and emergency treatment. We assumed that treatments received within one week from diagnosis are highly likely to have been delivered in emergency circumstances. Unexpectedly, we found that a larger proportion of patients in the upper socioeconomic groups were treated within one week, relative to more disadvantaged patients. This finding might be partly explained by a larger use of the private health care sector by more affluent patients in their pursuit of a diagnosis. A similar problem might exist at the opposite end of the time-to-treatment spectrum, if treatments delivered privately were not recorded in cancer registries. However, all the registries concerned have established links with private health care facilities which make these potential sources of bias unlikely to affect our findings to any meaningful extent. More generally, it was not possible to distinguish cases for which information on treatment was missing from those which genuinely received no treatment within the relevant time-frame.

Our study provides evidence of a persistent socioeconomic gradient in survival among patients receiving late treatment. This finding may reflect differences in unobserved tumour or treatment characteristics among socioeconomic groups. Unfortunately, the information recorded in the three cancer registries was too often not detailed enough or missing on aspects such as the nature of surgical interventions (e.g. curative vs. palliative; different types of resection) or the nature of neo-adjuvant and adjuvant therapies received by patients. Patients in the most affluent groups, who are also likely to be better educated, may be able to obtain more appropriate and higher quality treatments. For instance, data from one of the registries covered by our study show a lower likelihood of breast conserving surgery in socioeconomically disadvantaged women³⁵. There is at least some evidence that physician perceptions of patients may be influenced by the patients' socio-demographic characteristics, which may ultimately affect referral patterns, diagnostic pathways and treatment recommendations³⁶. Other non clinical factors, such as willingness to participate in treatment, might contribute to a higher colorectal cancer mortality in the lower socioeconomic groups³⁷. All of these hypotheses warrant further investigation.

Our measure of access to treatment was based on the time elapsed between the date of the first known contact within the NHS (excluding primary care) and the date of first treatment. However, the time since the onset of clinical symptoms or the first contact with a general practitioner, not available in our data, may also affect survival. The latter, which may be a reflection of awareness of cancer risk, are also likely to vary by socioeconomic condition³⁸. Time-to-treatment has been defined in a variety of ways in previous studies, making comparisons across studies difficult. Examples include time elapsed between first symptoms^{9,39}, first medical consultation³⁹ or outpatient attendance⁴⁰, or first presentation of initial symptoms to a doctor⁴¹, and hospital admission⁴² or treatment^{9,40,41}.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Individuals were assigned to socioeconomic groups on the basis of an ecological measure of socioeconomic status, the Townsend index, measured at the Ward level. Life tables for different socioeconomic groups were based on a different ecological measure, the income domain of the Index of Multiple Deprivation (IMD)¹⁹. However, previous research has shown that different indices of area deprivation lead to similar estimates of socioeconomic gradients, and what makes the largest difference is the geographical level at which they are measured⁴³. Assessing area deprivation at the Ward level is likely to underestimate socioeconomic gradients in cancer treatment and survival to a certain degree, relative to what would have been observed if individual-level or smaller-area-level information had been available.

In conclusion, we showed how access to treatment for colorectal cancer varies in different socioeconomic groups. Differences in access to treatment did not seem to play a direct role in explaining overall socioeconomic disparities in colorectal cancer survival while tumour stage at diagnosis partly explained these disparities. However, our findings also suggested that disparities in survival were greatly attenuated among patients receiving early treatment. This observation reinforces the idea that equal treatment may lead to equal outcomes, whatever the socioeconomic level. Access to treatment is a multidimensional concept and factors other than those captured by our measure of access, such as quality of care and patient preferences in relation to treatment might play a role in generating socioeconomic disparities in survival.

Table 1. Characteristics of study population by deprivation category

For Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

Table 2. Association of treatment and time-to-treatment (absence of treatment* taken as reference category) with deprivation (n=71 917)

For Review Only

Table 3. Excess hazard ratio of death up to three years since diagnosis by deprivation category
(n=71 917)

For Review Only

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60

REFERENCES

¹ World Health Organization [homepage on the Internet]. [updated 2009 February]. Available from: <http://www.who.int/mediacentre/factsheets/fs297/en/index.html>.

² Mitry E, Rachet B. [Prognosis of colorectal cancer and socio-economic inequalities]. *Gastroenterol Clin Biol* 2006; 30: 598-603.

³ Shack LG, Rachet B, Brewster DH, Coleman MP. Socioeconomic inequalities in cancer survival in Scotland 1986-2000. *Br J Cancer* 2007; 97: 999-1004.

⁴ Woods LM, Rachet B, Coleman MP. Origins of socio-economic inequalities in cancer survival: a review. *Ann Oncol* 2006; 17: 5-19.

⁵ Ionescu MV, Carey F, Tait IS, Steele RJ. Socioeconomic status and stage at presentation of colorectal cancer. *Lancet* 1998; 352: 1439.

⁶ Brewster DH, Thomson CS, Hole DJ, Black RJ, Stroner PL, Gillis CR. Relation between socioeconomic status and tumour stage in patients with breast, colorectal, ovarian, and lung cancer: results from four national, population based studies. *Br Med J* 2001; 322: 830-1.

⁷ Hole DJ, McArdle CS. Impact of socioeconomic deprivation on outcome after surgery for colorectal cancer. *Br J Surg* 2002; 89: 586-90.

⁸ Schrijvers CT, Mackenbach JP, Lutz JM, Quinn MJ, Coleman MP. Deprivation, stage at diagnosis and cancer survival. *Int J Cancer* 1995; 63: 324-9.

⁹ Langenbach MR, Schmidt J, Neumann J, Zirngibl H. Delay in treatment of colorectal cancer: multifactorial problem. *World J Surg* 2003; 27: 304-8.

¹⁰ Morris E, Quirke P, Thomas JD, Fairley L, Cottier B, Forman D. Unacceptable variation in abdominoperineal excision rates for rectal cancer: time to intervene? *Gut* 2008; 57: 1690-7.

¹¹ VanEenwyk J, Campo JS, Ossiander EM. Socioeconomic and demographic disparities in treatment for carcinomas of the colon and rectum. *Cancer* 2002; 95: 39-46.

- ¹² World Health Organization. International classification of diseases for Oncology, 10th revision [homepage on the Internet]. [updated 2009]. Available from: <http://www.who.int/classifications/icd/en/>.
- ¹³ Gatta G, Faivre J, Capocaccia R, Ponz de Leon M. Survival of colorectal cancer patients in Europe during the period 1978-1989. *Eur J Cancer* 1998; 34: 2176-83.
- ¹⁴ American Joint Committee on Cancer. Cancer Staging Manual. Springer, 2002, 113-24.
- ¹⁵ Health and deprivation: Inequality and the North. London. Townsend P, Phillimore P, Beattie A, 1988.
- ¹⁶ Office for National Statistics. Census 2001. Office for National Statistics [homepage on the Internet]. [updated 2009 July 22]. Available from: <http://www.statistics.gov.uk/CCI/SearchRes.asp?term=2001+census>.
- ¹⁷ Esteve J, Benhamou E, Croasdale M, Raymond L. Relative survival and the estimation of net survival: elements for further discussion. *Stat Med* 1990; 9: 529-38.
- ¹⁸ Coleman MP, Rachet B, Woods LM *et al.*,. Trends and socioeconomic inequalities in cancer survival in England and Wales up to 2001. *Br J Cancer* 2004; 90: 1367-73.
- ¹⁹ Communities and Local Government. Indices of Deprivation [homepage on the Internet]. [updated 2009 July 22]. Available from: <http://www.communities.gov.uk/communities/neighbourhoodrenewal/deprivation/>.
- ²⁰ Dickman PW, Sloggett A, Hills M, Hakulinen T. Regression models for relative survival. *Stat Med* 2004; 23: 51-64.
- ²¹ Little RJA, Rubin DB. Statistical Analysis with Missing Data. New York. J. Wiley & Sons, 1987.
- ²² Rubin DB. Multiple Imputation for Nonresponse in Surveys. New York. J. Wiley & Sons, 1987.

- ²³ Rubin DB. Multiple imputation after 18+ years (with discussion) *J Am Stat Ass* 1996; 91: 473-89.
- ²⁴ Schafer JL. Analysis of Incomplete Multivariate Data. London. Chapman & Hall, 1997.
- ²⁵ Mitry E, Rachet B, Quinn MJ, Cooper N, Coleman MP. Survival from cancer of the colon in England and Wales up to 2001. *Br J Cancer* 2008; 99 Suppl 1: S26-9.
- ²⁶ Mitry E, Rachet B, Quinn MJ, Cooper N, Coleman MP. Survival from cancer of the rectum in England and Wales up to 2001. *Br J Cancer* 2008; 99 Suppl 1: S30-2.
- ²⁷ Schrijvers CT, Coebergh JW, van der Heijden LH, Mackenbach JP. Socioeconomic variation in cancer survival in the southeastern Netherlands, 1980-1989. *Cancer* 1995; 75: 2946-53.
- ²⁸ Kaffashian F, Godward S, Davies T, Solomon L, McCann J, Duffy SW. Socioeconomic effects on breast cancer survival: proportion attributable to stage and morphology. *Br J Cancer* 2003; 89: 1693-6.
- ²⁹ Shack L. What factors influence socioeconomic inequalities in colorectal cancer survival? [PhD dissertation]. London. The London School of Hygiene and Tropical Medicine. Department of Epidemiology and Population Health, 2009.
- ³⁰ Singh GK, Miller BA, Hankey BF, Edwards BK. Area Socioeconomic Variations in U.S. Cancer Incidence, Mortality, Stage, Treatment, and Survival, 1975–1999 [monograph on the internet]. National Cancer Institute, 2003. Available from:<http://seer.cancer.gov/publications/ses/contents.pdf>.
- ³¹ Morris S, Sutton M, Gravelle H. Inequity and inequality in the use of health care in England: an empirical investigation. *Soc Sci Med* 2005; 60: 1251-66.
- ³² Nur U, Rachet B, Parmar MK *et al.*,. No socioeconomic inequalities in colorectal cancer survival within a randomised clinical trial. *Br J Cancer* 2008; 99: 1923-8.

- 1
 - 2
 - 3
 - 4
 - 5
 - 6
 - 7
 - 8
 - 9
 - 10
 - 11
 - 12
 - 13
 - 14
 - 15
 - 16
 - 17
 - 18
 - 19
 - 20
 - 21
 - 22
 - 23
 - 24
 - 25
 - 26
 - 27
 - 28
 - 29
 - 30
 - 31
 - 32
 - 33
 - 34
 - 35
 - 36
 - 37
 - 38
 - 39
 - 40
 - 41
 - 42
 - 43
 - 44
 - 45
 - 46
 - 47
 - 48
 - 49
 - 50
 - 51
 - 52
 - 53
 - 54
 - 55
 - 56
 - 57
 - 58
 - 59
 - 60
- ³³ Nur U, Shack LG, Rachet B, Carpenter JR, Coleman MP. Modelling relative survival in the presence of incomplete data: a tutorial. [Epub ahead of print]. *Int J Epidemiol* 2009; 1-11
- ³⁴ Sterne JA, White IR, Carlin JB *et al.*,. Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. *Br Med J* 2009; 338: b2393
- ³⁵ Downing A, Prakash K, Gilthorpe MS, Mikeljevic JS, Forman D. Socioeconomic background in relation to stage at diagnosis, treatment and survival in women with breast cancer. *Br J Cancer* 2007; 96: 836-40.
- ³⁶ van Ryn M, Burke J. The effect of patient race and socio-economic status on physicians' perceptions of patients. *Soc Sci Med* 2000; 50: 813-28.
- ³⁷ Shavers VL, Brown ML. Racial and ethnic disparities in the receipt of cancer treatment. *J Natl Cancer Inst* 2002; 94: 334-57.
- ³⁸ Robb KA, Miles A, Campbell J, Evans P, Wardle J. Can cancer risk information raise awareness without increasing anxiety? A randomized trial. *Prev Med* 2006; 43: 187-90.
- ³⁹ Richards MA, Westcombe AM, Love SB, Littlejohns P, Ramirez AJ. Influence of delay on survival in patients with breast cancer: a systematic review. *Lancet* 1999; 353: 1119-26.
- ⁴⁰ Comber H, Cronin DP, Deady S, Lorcaín PO, Riordan P. Delays in treatment in the cancer services: impact on cancer stage and survival. *Ir Med J* 2005; 98: 238-9.
- ⁴¹ Robertson R, Campbell NC, Smith S *et al.*,. Factors influencing time from presentation to treatment of colorectal and breast cancer in urban and rural areas. *Br J Cancer* 2004; 90: 1479-85.
- ⁴² Ciccone G, Prastaro C, Ivaldi C, Giacometti R, Vineis P. Access to hospital care, clinical stage and survival from colorectal cancer according to socio-economic status. *Ann Oncol* 2000; 11: 1201-4.
- ⁴³ Woods LM, Rachet B, Coleman MP. Choice of geographic unit influences socioeconomic inequalities in breast cancer survival. *Br J Cancer* 2005; 92: 1279-82.

1
2 **this Table 1 will be replaced by New Table 1**

3 Table 1. Characteristics of study population by deprivation category

		All		Most affluent		2		3		4		Most deprived	
		N	%	N	%	N	%	N	%	N	%	N	%
		71,917		11,070		12,848		14,406		14,461		19,132	
Sex													
Men		38,385	53	5944	54	6795	53	7581	53	7669	53	10,396	54
Women		33,532	47	5126	46	6053	47	6825	47	6792	47	8736	46
Age at diagnosis													
15-49		3533	5	530	5	560	5	667	5	701	5	1075	6
50-59		8195	11	1393	13	1467	11	1597	11	1621	11	2117	11
60-69		17,038	24	2758	25	2991	23	3258	23	3340	23	4691	24
70-79		25,288	35	3698	33	4561	36	5066	35	5134	36	6829	36
80+		17,863	25	2691	24	3269	25	3818	26	3665	25	4420	23
Stage at diagnosis													
local		14,476	20	2599	24	2815	22	2956	21	2796	19	3310	17
extension beyond organ		18,930	26	2753	25	3346	26	3746	26	3902	28	5183	27
regional lymph node involvement		19,053	27	2925	26	3385	26	3882	27	3818	26	5044	27
metastasis		19,457	27	2793	25	3302	26	3822	26	3945	27	5595	29
Tumour site													
colon		50,935	71	7939	72	9093	71	10,238	71	10,198	71	13,467	70
rectum		20,982	29	3131	28	3755	29	4168	29	4263	29	5665	30
Morphology group													
adenocarcinoma in polyp / adenoma		2565	4	339	3	421	3	499	4	533	4	773	4
mucinous adenocarcinoma		4720	7	761	7	864	7	998	7	963	7	1134	6
other adenocarcinoma		54,941	76	8,529	77	9887	77	10,998	76	10,944	76	14,583	76
other carcinoma and carcinoma NOS		8542	12	1340	12	1537	12	1707	12	1769	12	2189	11
sarcoma and unspecified		1149	1	101	1	139	1	204	1	252	1	453	3
Treatment													
within first week		14,089	20	2367	21	2678	21	2851	20	2615	18	3578	19
within 2-4th week		14,930	21	2431	22	2629	20	3017	21	2928	20	3925	20
within 2-3rd month		20,482	28	3078	28	3723	29	4146	29	4202	29	5333	28
within 4-6th month		5621	8	769	7	925	7	1141	8	1235	9	1551	8
no treatment within 6 months		16,795	23	2425	22	2893	23	3251	22	3481	24	4745	25

1

2 new Table 1 to include in the revised manuscript replacing the old table 1

3 Table 1. Characteristics of study population by deprivation category

	All		Most affluent		2		3		4		Most deprived	
	N	%	N	%	N	%	N	%	N	%	N	%
	71,917		11,070		12,848		14,406		14,461		19,132	
Sex												
Men	38,385	53	5944	54	6795	53	7581	53	7669	53	10,396	54
Women	33,532	47	5126	46	6053	47	6825	47	6792	47	8736	46
Age at diagnosis												
15-49	3533	5	530	5	560	5	667	5	701	5	1075	6
50-59	8195	11	1393	13	1467	11	1597	11	1621	11	2117	11
60-69	17,038	24	2758	25	2991	23	3258	23	3340	23	4691	24
70-79	25,288	35	3698	33	4561	36	5066	35	5134	36	6829	36
80+	17,863	25	2691	24	3269	25	3818	26	3665	25	4420	23
Stage at diagnosis^a												
local	14,476	20	2599	24	2815	22	2956	21	2796	19	3310	17
extension beyond organ	18,930	26	2753	25	3346	26	3746	26	3902	28	5183	27
regional lymph node involvement	19,053	27	2925	26	3385	26	3882	27	3818	26	5044	27
metastasis	19,457	27	2793	25	3302	26	3822	26	3945	27	5595	29
(missing) ^b		(17)		(17)		(15)		(15)		(17)		(19)
Tumour site												
colon	50,935	71	7939	72	9093	71	10,238	71	10,198	71	13,467	70
rectum	20,982	29	3131	28	3755	29	4168	29	4263	29	5665	30
Morphology group												
adenocarcinoma in polyp / adenoma	2565	4	339	3	421	3	499	4	533	4	773	4
mucinous adenocarcinoma	4720	7	761	7	864	7	998	7	963	7	1134	6
other adenocarcinoma	54,941	76	8,529	77	9887	77	10,998	76	10,944	76	14,583	76
other carcinoma and carcinoma NOS	8542	12	1340	12	1537	12	1707	12	1769	12	2189	11
sarcoma and unspecified	1149	1	101	1	139	1	204	1	252	1	453	3
Treatment												
within first week	14,089	20	2367	21	2678	21	2851	20	2615	18	3578	19
within 2-4th week	14,930	21	2431	22	2629	20	3017	21	2928	20	3925	20
within 2-3rd month	20,482	28	3078	28	3723	29	4146	29	4202	29	5333	28
within 4-6th month	5621	8	769	7	925	7	1141	8	1235	9	1551	8
no treatment within 6 months	16,795	23	2425	22	2893	23	3251	22	3481	24	4745	25

33 Frequencies and proportions derived from the 10 completed data sets

34 ^bProportions of missing stage observed in the original data set

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Table 2. Association of receipt of treatment and time-to-treatment (absence of treatment* taken as reference category) with deprivation (n=71 917)

		Time-to-treatment (<i>versus</i> no treatment)			
	Receipt of treatment (Yes <i>versus</i> No)*	Treatment in 1st week (95% CI)	Treatment within 1st month (95% CI)	Treatment within 2- 3rd month (95% CI)	Treatment within 4-6th month (95% CI)
unadjusted OR					
1 (<i>most affluent</i>)	1.00	1.00	1.00	1.00	1.00
2	0.97 (0.91-1.03)	0.95 (0.88-1.02)	0.91 (0.84-0.98)	1.01 (0.94-1.09)	1.01 (0.90-1.13)
3	0.96 (0.91-1.02)	0.90 (0.83-0.97)	0.93 (0.86-1.00)	1.00 (0.94-1.08)	1.11 (1.00-1.23)
4	0.88 (0.83-0.94)	0.77 (0.71-0.83)	0.84 (0.78-0.90)	0.95 (0.89-1.02)	1.12 (1.01-1.24)
5 (<i>most deprived</i>)	0.85 (0.80-0.90)	0.77 (0.72-0.83)	0.83 (0.77-0.89)	0.89 (0.83-0.95)	1.03 (0.93-1.14)
adjusted OR**					
1 (<i>most affluent</i>)	1.00	1.00	1.00	1.00	1.00
2	0.99 (0.93-1.06)	0.97 (0.89-1.05)	0.93 (0.86-1.01)	1.05 (0.97-1.13)	1.04 (0.93-1.16)
3	1.01 (0.95-1.08)	0.93 (0.86-1.01)	0.97 (0.90-1.05)	1.06 (0.99-1.15)	1.17 (1.05-1.30)
4	0.91 (0.86-0.97)	0.79 (0.73-0.85)	0.87 (0.80-0.94)	0.99 (0.92-1.07)	1.16 (1.05-1.30)
5 (<i>most deprived</i>)	0.87 (0.82-0.92)	0.78 (0.72-0.84)	0.84 (0.78-0.90)	0.91 (0.85-0.98)	1.07 (0.96-1.18)

Treatment within 6 months after first contact within NHS
*Adjustement for age at first attendance and stage at diagnosis

Table 3. Excess hazard ratio of death up to three years since diagnosis by deprivation category (n=71 917)

		Excess Hazard Ratio of death (95% CI)				
	All patients	Treatment in 1st week	Treatment within 1st month	Treatment within 2-3rd month	Treatment within 4-6th month	No treatment
Unadjusted						
Deprivation						
1 (most affluent)	1.00					
2	1.07 (1.02-1.12)					
3	1.12 (1.07-1.17)					
4	1.18 (1.13-1.23)					
5 (most deprived)	1.20 (1.16-1.25)					
Model including treatment						
Deprivation						
1 (most affluent)	1.00	1.00	1.00	1.00	1.00	1.00
2	1.07 (1.03-1.12)	1.00 (0.91-1.10)	1.03 (0.92-1.14)	1.14 (1.02-1.27)	1.04 (0.82-1.32)	1.11 (1.03-1.19)
3	1.15 (1.10-1.20)	1.06 (0.97-1.16)	1.09 (0.98-1.20)	1.13 (1.01-1.25)	1.07 (0.85-1.35)	1.25 (1.17-1.33)
4	1.20 (1.15-1.25)	1.12 (1.02-1.23)	1.17 (1.06-1.30)	1.12 (1.01-1.24)	1.10 (0.88-1.37)	1.31 (1.22-1.39)
5 (most deprived)	1.20 (1.16-1.25)	1.06 (0.97-1.16)	1.11 (1.01-1.22)	1.24 (1.13-1.37)	1.17 (0.94-1.45)	1.30 (1.22-1.39)
Model including treatment, age at first attendance and stage at diagnosis						
Deprivation						
1 (most affluent)	1.00	1.00	1.00	1.00	1.00	1.00
2	1.04 (0.99-1.08)	0.99 (0.90-1.09)	0.99 (0.89-1.10)	1.13 (1.02-1.25)	1.01 (0.81-1.27)	1.04 (0.96-1.12)
3	1.09 (1.05-1.14)	1.08 (0.99-1.19)	1.02 (0.93-1.13)	1.11 (1.01-1.22)	1.04 (0.85-1.29)	1.14 (1.06-1.22)
4	1.15 (1.10-1.20)	1.12 (1.02-1.24)	1.12 (1.01-1.23)	1.14 (1.03-1.26)	1.03 (0.84-1.26)	1.20 (1.12-1.29)
5 (most deprived)	1.12 (1.07-1.17)	1.05 (0.96-1.14)	1.04 (0.95-1.15)	1.20 (1.09-1.31)	1.14 (0.93-1.39)	1.15 (1.08-1.24)

* Presence of treatment within 6 months after first contact within NHS

Tables 2 and 3 to include in the revised manuscript

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49

Supplementary Table 2 (for the reviewer only). Association of receipt of treatment and time-to-treatment (absence of treatment* taken as reference category) with depriv:

		Time-to-treatment (<i>versus</i> no treatment)			
	Receipt of treatment (Yes <i>versus</i> No)*	Treatment in 1st week (95% CI)	Treatment within 1st month (95% CI)	Treatment within 2-3rd month (95% CI)	Treatment within 4-6th month (95% CI)
unadjusted OR					
1 (most affluent)	1.00	1.00	1.00	1.00	1.00
2	0.94 (0.87-1.01)	0.92 (0.84-1.01)	0.87 (0.80-0.96)	0.99 (0.91-1.07)	0.98 (0.87-1.10)
3	0.94 (0.88-1.01)	0.89 (0.81-0.97)	0.89 (0.82-0.97)	0.99 (0.92-1.08)	0.98 (0.94-1.19)
4	0.93 (0.86-1.00)	0.81 (0.74-0.88)	0.87 (0.80-0.95)	1.01 (0.93-1.09)	1.14 (1.02-1.28)
5 (most deprived)	0.94 (0.88-1.01)	0.86 (0.79-0.94)	0.90 (0.83-0.97)	0.99 (0.92-1.07)	1.08 (0.97-1.21)
adjusted OR**					
1 (most affluent)	1.00	1.00	1.00	1.00	1.00
2	0.95 (0.88-1.03)	0.93 (0.85-1.02)	0.89 (0.81-0.98)	1.01 (0.92-1.10)	0.99 (0.88-1.12)
3	0.96 (0.89-1.04)	0.90 (0.82-0.98)	0.91 (0.83-1.00)	1.03 (0.94-1.12)	1.09 (0.97-1.23)
4	0.93 (0.86-1.00)	0.80 (0.73-0.88)	0.87 (0.80-0.95)	1.02 (0.94-1.11)	1.16 (1.03-1.30)
5 (most deprived)	0.94 (0.88-1.01)	0.86 (0.78-0.93)	0.90 (0.83-0.98)	1.01 (0.93-1.09)	1.10 (0.98-1.24)

Treatment within 6 months after first contact within NHS
*Adjustement for age at first attendance and stage at diagnosis

Table 3 provided for the reviewer only (not to be included in the revised manuscript)

Supplementary Table 3 (for the reviewer only). Excess hazard ratio of death up to three years since diagnosis by deprivation category (n=59 848)

		Excess Hazard Ratio of death (95% CI)				
	All patients	Treatment in 1st week	Treatment within 1st month	Treatment within 2-3rd month	Treatment within 4-6th month	No treatment
Unadjusted						
Deprivation						
1 (most affluent)	1.00					
2	1.07 (1.02-1.12)					
3	1.11 (1.06-1.16)					
4	1.14 (1.08-1.19)					
5 (most deprived)	1.18 (1.13-1.24)					
Model including treatment						
Deprivation						
1 (most affluent)	1.00	1.00	1.00	1.00	1.00	1.00
2	1.07 (1.02-1.13)	1.02 (0.92-1.13)	1.01 (0.90-1.14)	1.13 (1.00-1.26)	1.03 (0.79-1.33)	1.11 (1.02-1.21)
3	1.13 (1.07-1.18)	1.08 (0.98-1.19)	1.07 (0.97-1.20)	1.11 (0.99-1.24)	1.08 (0.84-1.38)	1.21 (1.11-1.32)
4	1.17 (1.11-1.23)	1.17 (1.06-1.30)	1.16 (1.04-1.29)	1.09 (0.97-1.22)	1.04 (0.82-1.32)	1.24 (1.14-1.35)
5 (most deprived)	1.22 (1.16-1.28)	1.12 (1.02-1.24)	1.12 (1.01-1.24)	1.22 (1.10-1.36)	1.12 (0.89-1.41)	1.36 (1.26-1.47)
Model including treatment, age at first attendance and stage at diagnosis						
Deprivation						
1 (most affluent)	1.00	1.00	1.00	1.00	1.00	1.00
2	1.03 (0.98-1.08)	1.01 (0.91-1.12)	0.97 (0.87-1.08)	1.12 (1.00-1.24)	1.00 (0.79-1.26)	1.02 (0.94-1.12)
3	1.08 (1.03-1.14)	1.11 (1.01-1.23)	1.00 (0.90-1.11)	1.10 (0.99-1.23)	1.07 (0.86-1.33)	1.11 (1.02-1.21)
4	1.14 (1.09-1.19)	1.17 (1.06-1.29)	1.09 (0.98-1.22)	1.13 (1.02-1.25)	0.98 (0.78-1.22)	1.19 (1.09-1.29)
5 (most deprived)	1.15 (1.09-1.20)	1.09 (0.99-1.21)	1.05 (0.95-1.17)	1.18 (1.06-1.29)	1.10 (0.89-1.36)	1.23 (1.14-1.34)

* Presence of treatment within 6 months after first contact within NHS